- Home
- GCDT vs SNTI Comparison
GCDT vs SNTI Comparison
Compare GCDT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | SNTI |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 53.6M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | GCDT | SNTI |
|---|---|---|
| Price | $4.81 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 655.7K | 341.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,130,401.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 216.53 | N/A |
| 52 Week Low | $4.15 | $1.02 |
| 52 Week High | $5.85 | $5.10 |
Technical Indicators
Market Signals| Indicator | GCDT | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.51 |
| Support Level | N/A | $1.02 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 87.53 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.